A randomized, quadruple crossover single-blind study on immediate action of Bufferin 81mg tablets and Bayaspirin 100mg in healthy volunteers
Not Applicable
- Conditions
- Acute myocardial infarction
- Registration Number
- JPRN-UMIN000002559
- Lead Sponsor
- Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1) history of hypersensitivity to ingredients of Bufferin 81mg tablets, Bayaspirin 100mg or salicylic acid formulation 2) history of aspirin asthma 3) use of non-steroidal anti-inflammatory drugs (NSAIDs) within past 2 weeks 4) antiplatelet agent dosed within past 2 weeks 5) anticoagulation drug dosed within past 2 weeks 6) odontectomy or other invasive operation scheduled within past 2 weeks 7) peptic ulcer disease 8) pregnancy, parturition or lactation 9) bleeding tendency 10) hypermenorrhea 11) drink alcohol on a regular basis 12) reflux esophagitis 13) other situation that doctor decides
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time-course of platelet aggregation inhibition
- Secondary Outcome Measures
Name Time Method Time-course of plasma concentration of aspirin after oral administration, pharmacokinetic parameters (Tmax, AUC), Time-course of plasma TXB2 level